Rutgers & Horizon plan to commercialize CRISPR base editing technology
Category: #health  By Saipriya Iyer  Date: 2019-01-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Rutgers & Horizon plan to commercialize CRISPR base editing technology

Horizon has also agreed to fund further research in base editing at the Rutgers University.

Horizon Discovery Group plc, one of the globally reputed gene editing industry contenders, has reportedly inked a partnership with The State University of New Jersey, Rutgers. As per reliable sources, the agreement has been forged for developing and commercializing a gene editing technology – called base editing, that finds applications in new cell therapy development and is expected to augment Horizon’s research tools and services.

Credible reports cite that Horizon will join hands with the Rutgers University to develop the novel base editing platform from Dr. Shengkan Jin laboratory. As a part of the agreement, Horizon has already made a non-material payment to Rutgers, garnering the option to exclusively license the base editing technology to be used in all therapeutic applications. Sources familiar with the knowledge of the matter also claim that Horizon will fund further research in base editing at the Rutgers University while simultaneously undertaking evaluation and proof-of-concept studies at Horizon.

A report published by Genomeweb claims Terry Pizzie, CEO, Horizon, to have stated that base editing is one of the most potentially transformative of all gene editing technologies and is equipped with the ability to target numerous diseases that so far have no treatment. As a global leader in the field of gene modulation and gene editing, both in the applied as well as research markets, Horizon is rather thrilled to join forces with the Rutgers University, Pizzie added.

Further commenting on the partnership, Pizzie said that by extending Horizon’s scientific and IP capabilities, the company will now be more than able to completely support its pharma, academic, and biotech partners to deliver enhanced cell therapy solutions to patients. Also, as a part of its five-year investment strategy, Horizon is committed to pouring in capital in high-grade technologies which maintain its market leadership – base editing technology being the case in point, he elaborates.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

New Medtronic Micra AV pacemaker receives approval from the U.S. FDA
New Medtronic Micra AV pacemaker receives approval from the U.S. FDA
By Saipriya Iyer

Medtronic plc, a renowned US-based medical device company, reportedly announced that its Micra AV pacemaker has received approval from the U.S. FDA. The Medtronic Micra AV is the world’s smallest pacemaker with A...

Health Canada grants two DIN to new Tetra Bio-pharma OTC products
Health Canada grants two DIN to new Tetra Bio-pharma OTC products
By Saipriya Iyer

Tetra Bio-pharma, a renowned Canadian biopharmaceutical company, reportedly announced that Health Canada, the regulatory health authority of Canada, has granted two new DIN (Drug Identification Numbers) for the first O...

Digital River & Magento team-up to create customized commerce solution
Digital River & Magento team-up to create customized commerce solution
By Saipriya Iyer

Digital River, a renowned global ecommerce facilitator for well-known and fast-growing brands, has reportedly signed a new strategic partnership deal with Magento, a leading provider of commerce innovations to retailer...